دانلود رایگان مقاله انگلیسی ارزیابی سودمندی درمان سرطان با روش Inhibitor Therapy روی بیماران - ASCO 2018

قیمت خرید این محصول

رایگان

دانلود مقاله انگلیسی سفارش ترجمه این مقاله

عنوان فارسی

ارزیابی سودمندی درمان سرطان با روش Inhibitor Therapy روی بیماران

عنوان انگلیسی

How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy?

صفحات مقاله فارسی

صفحات مقاله انگلیسی

سال انتشار

2018

فرمت مقاله انگلیسی

PDF

نشریه

ASCO

کد محصول

E6102

رشته های مرتبط با این مقاله

پزشکی

گرایش های مرتبط با این مقاله

ایمنی شناسی، انکولوژی

مجله

انجمن آمریکایی انکولوژی بالینی - American Society of Clinical Oncology

دانشگاه

University of California Los Angeles - Jonsson Comprehensive Cancer Center - Los Angeles - CA

برای سفارش ترجمه این مقاله با کیفیت عالی و در کوتاه ترین زمان ممکن توسط مترجمین مجرب سایت ایران عرضه؛ روی دکمه سبز رنگ کلیک نمایید.

بخشی از متن مقاله

In recent years, immunotherapy has revolutionized the treatment of cancer. Immunotherapy has been used for decades (vaccines, interferon, high-dose interleukin 2), but only since the introduction of checkpoint inhibitors has it had a significant impact on the survival of patients with a variety of cancers. Currently, checkpoint inhibitors involving two specific targets are approved by the US Food and Drug Administration: cytotoxic T-cell lymphocyte-4–blocking antibodies (ipilimumab, approved by the US Food and Drug Administration for patients with melanoma) and programmed cell death protein 1/programmed death ligand 1–blocking antibodies (atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab for patients with melanoma, renal cell carcinoma, non–small-cell lung cancer, head and neck cancer, bladder cancer, Merkel cell carcinoma, Hodgkin lymphoma, and others). As clinical trials with checkpoint inhibitors were ongoing, it was noted that occasionally atypical patterns of responses (a transient increase in the size of lesions or even appearance of new lesions) were seen, and therefore the most commonly used response criteria, namely Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, may not capture all patients who received benefit from these therapies.

برچسب‌ها: دانلود رایگان مقالات انگلیسی پزشکی